ARQT — Arcutis Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $3.66bn
- $3.53bn
- $376.07m
Brief: Arcutis Biotherapeutics Says Majority Of Individuals With Co's Atopic Dermatitis Improved Roflumilast Cream 0.15%
Brief: Arcutis Biotherapeutics Says Zoryve Topical Foam, 0.3% Clears Seborrheic Dermatitis
Brief: Arcutis Canada Announces Health Canada Acceptance Of The Supplement To A New Drug Submission For Roflumilast
U.S. RESEARCH ROUNDUP-Amazon.Com, BlackRock, WW Grainger
U.S. STOCKS ON THE MOVE-Biomerica, Netflix, SunPower
U.S. STOCKS ON THE MOVE-Occidental Petroleum, Scorpio Tankers, ZimVie
U.S. STOCKS ON THE MOVE-Micron, PGT Innovations, Adobe
U.S. STOCKS ON THE MOVE-GSK, Illumina, Nio
Arcutis jumps after US FDA approves skin disease drug
Brief: Huadong Medicine Says Unit, Arcutis Biotherapeutics' Drug Gets US FDA Approval
Brief: FDA Approves Arcutis’(Roflumilast) Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And Older
Arcutis Biotherapeutics rises on FDA approval for drug to treat chronic skin disease
US FDA approves Arcutis' drug to treat chronic skin disease (updated)
US FDA approves Arcutis' drug to treat chronic skin disease
U.S. RESEARCH ROUNDUP- Pioneer Natural Resources,Oxford Industries, Nutrien
Arcutis Biotherapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Arcutis Biotherapeutics Q3 basic EPS USD -0.73
Arcutis Biotherapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Brief: Arcutis Biotherapeutics Says New Data Shows ZORYVE Cream 0.3% Provided Measurable Improvement Of Plaque Psoriasis